Posts Tagged ‘medical’

Study: Stem Cells Reverse Heart Damage – Video

Wednesday, February 22nd, 2012


15-02-2012 13:09 BY ALYSSA CARTEE ANCHOR MEGAN MURPHY A breakthrough discovery in stem cell treatments. A patient’s own stem cells could actually regenerate the heart after a heart attack. WFLD explains the findings. “The studies found that recent heart attack victims who receive stem cell infusions had a drop in unhealthy heart scar tissue from 24 to 12 percent.” The procedure is minimally invasive. A catheter is inserted through the patient’s vein and a piece of heart muscle about the size of a peppercorn is removed. That biopsied tissue is then grown in a petri dish and reintroduced to the damaged portion of the heart. This new procedure could change the way heart attacks are treated. ABC reports the typical damage a heart attack leaves and the limited options for treatment. “The damaged scar tissue that results from a heart attack diminishes heart function, which can ultimately lead to enlargement of the heart. At best … there are measures doctors can try to reduce or compensate for the damage, but in many cases, heart failure ultimately sets in, often requiring mechanical support or a transplant.” But the new treatment challenges the conventional wisdom that once the heart is damaged, it can’t be repaired. Doctor Sanjay Gupta told CNN this breakthrough in the use of stem cells means a few different things for the medical community. “We’ve been talking about the promise of stem cells for so long but people have really yet to see it in action. … It really proved two things. First

View original post here:
Study: Stem Cells Reverse Heart Damage – Video

Scientists using stem cells to grow hamburger in a lab

Wednesday, February 22nd, 2012

Test-tube burgers – coming soon to a restaurant near you?

A researcher from the Netherlands says he expects to grow the first-ever hamburger in a lab by this fall.  The beef will made from bovine stem cells grown in a petri dish.

Dr. Mark Post, the study leader, said the ultimate goal is the mass produce the lab meat in order to cut back on cattle farming.

Personally, I have a few problems with this study.  Yes, the beef will be made from stem cells, but don’t be confused: There is nothing natural about growing meat in the laboratory for human consumption.

With all the controversy on genetically altered food why in the world would we want to get into the business of creating hamburgers in a lab?

To me the whole concept of farming animals and crops is that the practice contributes to the natural process of life.  The more natural the process, the healthier it is, in my opinion.

Many of the medical crises we’re seeing in the world today are partly due to some of the unnatural ways we’re manufacturing food – from the chemicals to preserve the taste, to the hormones to increase the size of produce, to the pesticides to control production.  At the end of the day, all of these factors are taking a toll on our society.

Now, I’m familiar with stem cell research, and I’m sure that Dr. Holt is creating very pure forms of muscle cells, but I believe the focus of stem cell regeneration should continue to be for the quest to eradicate human diseases.

To take this promising medical technology and commercialize it in such a way to create a for-profit industry like making hamburger patties to stock your local grocery store is disrespectful to the thousands of scientists who have studied – and continue to study – the life-saving potential of stem cells.

But maybe I’m wrong – tell me what you think.  Would you eat this burger?

Go here to see the original:
Scientists using stem cells to grow hamburger in a lab

Fibrosis – Targeting MicroRNA-21 May Have Therapeutic Benefit

Wednesday, February 22nd, 2012

Editor's Choice
Academic Journal
Main Category: Genetics
Article Date: 21 Feb 2012 – 10:00 PST

email to a friend   printer friendly   opinions  

Current Article Ratings:

Patient / Public: Healthcare Prof:
Fibrosis is a harmful build-up of excessive fibrous tissue that results in scarring, and ultimately, the loss of organ function. Although it can affect any tissue and organ system, it is most common in the heart, liver, lung, peritoneum, and kidney. The fibrotic scar tissue consists of extra-cellular matrix proteins, such as type I collagen, proteoglycans and fibronectin.

Regulus, a biopharmaceutical leader in the discovery and development of innovative medications that targets microRNAs, has discovered a number of microRNAs that impair the physiological regulatory mechanism in fibrosis, and has announced their new preclinical study results in the Science Translational Medicine journal, demonstrating that miR-21 contributed to fibrogenesis, and that it can be a suitable candidate as a target for anti-fibrotic therapies.

MicroRNA in humans are small RNA molecules that are typically 20 to 25 nucleotides in length, which do not encode proteins, but regulate gene expression. Discovered in the last decade, they represent one of the most exciting scientific breakthroughs in recent history. Researchers have discovered over 700 microRNAs in the human genome, with more than a third of all human genes thought to be regulated by microRNAs.

Given that a single microRNA is able to regulate entire networks of genes, these molecules are considered master regulators of the human genome. microRNAs have demonstrated their integral role in several biological processes, such as in immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development.

Most microRNAs are conserved across multiple species, which suggests that these molecules have an evolutionary importance as modulators of critical biological pathways. microRNA expression or function, has demonstrated to substantially alter in many states if diseases, such as cancer, heart failure and viral infections.

By targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of microRNAs, or miR-mimics, double-stranded oligonucleotides to replace microRNA function, research has discovered a new potential for a novel class of therapeutics that provide a unique approach for the treatment of diseases by modulating entire biological pathways.

Neil W. Gibson, Ph.D., Regulus' Chief Scientific Officer announced:

“We are pleased with the published results demonstrating that targeting miR-21 with proprietary anti-miR oligonucleotides is effective at preventing kidney fibrosis in preclinical models. We plan to select an anti-miR-21 development candidate this year for advancement into the clinic in the near future and are excited about the potential to bring this innovative treatment to patients with fibrotic diseases.”

Dr. Duffield, M.D., Ph.D. Associate Professor of Medicine, in the Division of Nephrology, at the University of Washington explained:

“Expression of miR-21 was found to be increased in fibrotic kidney samples from animal models and human patient samples. Genetic deletion of miR-21 in preclinical models protected kidneys from fibrosis and treatment with anti-miRs targeting miR-21 also blocked fibrosis in preclinical models. Taken together, these data suggest that anti-miR-21 could have a therapeutic benefit in patients with chronic kidney disease.”

The study focused on fibrosis targets miR-21 that increase cells in fibrotic tissues of humans. According to Regulus' earlier preclinical research, therapeutic oligonucleotides targeting miR-21 (anti-miR-21) has the ability to lower fibrosis in preclinical models through reducing the expression of extracellular matrix proteins. Even though many people are currently affected by fibrosis-related disease, few therapies are available to specifically treat this devastating illness.

Regulus and collaborators from the University of Washington examined the effect of miR-21 in kidney fibrosis, and even though they discovered no overt abnormality when genetically deleting miR-21 in mice, they did observe that these miR-21 knock out mice experienced less fibrosis in response to kidney injury, which was pheno-copied in wild-type mice treated with anti-miR-21 oligonucleotides.

The researchers analyzed gene expression profiles and detected groups of genes, especially those involved in lipid metabolism and enhanced oxygen radical production, that were involved in metabolic pathways that were up-regulated in the absence of miR-21. They observed that by systematically administering anti-miR-21, the harmful effects of miR-21 in kidney injuries were successfully reversed.

The results of the two mouse model studies prove that miR-21 contributes to fibrogenesis and epithelial injury in the kidneys. Furthermore, the findings support that miR-21 is a suitable candidate target for anti-fibrotic therapies.

Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our genetics section for the latest news on this subject. “MicroRNA 21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways”
Science Translational Medicine Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Petra Rattue. “Fibrosis – Targeting MicroRNA-21 May Have Therapeutic Benefit.” Medical News Today. MediLexicon, Intl., 21 Feb. 2012. Web.
22 Feb. 2012. <http://www.medicalnewstoday.com/articles/241959.php>

APA

Please note: If no author information is provided, the source is cited instead.


Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


More:
Fibrosis – Targeting MicroRNA-21 May Have Therapeutic Benefit

California Health Plans Improve on Quality Measures for Diabetes Care, Exceed National Average

Wednesday, February 22nd, 2012

SACRAMENTO, CA–(Marketwire -02/22/12)- California Health Maintenance Organizations (HMOs) and Preferred Provider Organizations (PPOs) improved on several quality measures this year including diabetes care, according to the 2012 Edition of the Health Care Quality Report Card released today by the California Office of the Patient Advocate (OPA). However, health plans performed below the national average in testing for lung disease; alcohol and drug dependence treatment; flu shots for adults; appropriately treating children with throat infections; and providing treatment for children with attention deficit disorder.

“As California implements health care reform, more focus will be placed on quality and value of health care,” said Office of the Patient Advocate Director Sandra Perez. “The Health Care Quality Report Card is an excellent tool that helps consumers sort out their choices and make decisions based on their personal health care needs.”

The Report Card provides consumers with the information needed to make informed choices regarding their health care. Highlights from the 2012 report card include:

Diabetes Care: HMOs exceeded national averages for most diabetes care measures by 7 to 10 percent and improved in controlling blood pressure and blood sugar. PPOs improved on testing for blood sugar, as well as testing for kidney function. Heart Care: HMOs improved on controlling high blood pressure and cholesterol when compared to the national average. Both HMOs and PPOs scored lower in this year's Report Card for administering heart attack medication. Clinical Conditions: HMOs exceeded national averages on the quality of care measures for most clinical conditions, while PPOs were slightly lower than national averages. Member Satisfaction: HMO and PPO member ratings improved regarding complaint resolution by 8 percent and 6.4 percent, respectively. However, 33 percent of HMO members and 43 percent of PPO members were still dissatisfied with complaint resolution. HMOs and PPOs have room to improve on testing for lung disease; alcohol and drug dependence treatment; flu shots for adults; appropriately treating children with throat infections; and providing treatment for children with attention deficit disorder.

Now in its 11th year, the report card contains quality and patient experience information for the state's nine largest HMOs, six largest PPOs and 212 medical groups representing 16 million California commercial health plan members.

“OPA's Health Care Quality Report Card sheds light on how well health plans are serving Californians. Californians deserve to get the right care at the right time to improve their health and stay healthy,” said Perez. “I am pleased by the progress made on several measures in quality of care and am encouraged at how health plans use this data to improve the care given to patients.”

The Health Care Quality Report Card has been a valuable tool for the health care industry in their efforts to make improvements.

Jerry Penso, MD, MBA, Medical Director, Sharp Rees-Stealy Medical Group, San Diego, who uses the data for quality of care improvements said, “We are proud to reach the 90th percentile of national performance on managing blood sugar and cholesterol for patients with diabetes as indicated in the Health Care Quality Report Card. Meeting these standards is more than just a score or a grade; it helps us save lives.”

Several new measures were added to the Report Card for 2012. For HMOs: aspirin use counseling for heart patients and immunizations for adolescents. For PPOs: additional diabetes and cardiovascular care measures; measures for prenatal and postpartum care; and immunizations for adolescents.

For more detailed information about the 2012 Edition Health Care Quality Report Card, visit www.opa.ca.gov. Copies of the Report Card can also be obtained by calling 1(888) 466-2219.

The California Office of the Patient Advocate was established in 2000 to represent the interests of health plan enrollees in California by educating them on their patient rights and responsibilities and publicly reporting on health care quality. The OPA website provides a one-stop-shop on health care quality reports covering health plans, medical groups, Medi-Cal, Healthy Families, hospitals, and long term care facilities. It also includes other resources to help consumers know their patient rights and get the most out of their health care.

See the article here:
California Health Plans Improve on Quality Measures for Diabetes Care, Exceed National Average

US record kidney donor chain ends

Wednesday, February 22nd, 2012

21 February 2012 Last updated at 11:08 ET

The world's longest chain of organ donations has been completed in the US, with 30 patients receiving a kidney from 30 living donors.

The chain connected people who had wanted to donate a kidney to a family member or friend, but were incompatible, with a suitable stranger.

Their loved one then received a kidney from someone else along the chain.

The complicated process lasted for four months and involved 17 hospitals across 11 states.

It started in August with a man called Rick Ruzzamenti, a 44-year-old electrician from California who decided he wanted to donate a kidney to a stranger.

It ended in December with 46-year-old Don Terry, of Joliet, Illinois, who has Type 2 diabetes and was at risk of dying of renal failure.

Because he had been unable to find a suitable donor within his family, Mr Terry had been put on a transplant waiting list and told it could take as long as five to 10 years.

A diabetes patient on dialysis typically does not have a long life expectancy and Mr Terry worried that he might not live to see his 50th birthday.

Continue reading the main story “Start Quote

I have made it my life's mission to make people aware of kidney chains”

End Quote Don Terry Organ recipient

“What bothered me the most was the possibility of leaving family members like my mom and dad by themselves, and having them see their son pass away from an excruciating disease,” he said.

'Love the stranger'

Mr Ruzzamenti's kidney was taken to New Jersey, to help a man whose own family wanted to donate but could not provide a suitable match.

The process continued until it reached the last donor in the chain – a 59-year-old California woman.

Her kidney was removed at the University of California, Los Angeles (UCLA) and flown to Loyola in Chicago to be given to Don Terry.

Mr Terry was unable to keep the chain going because his only sibling, a brother, is dead, and his elderly parents were unable to donate for medical reasons.

Following the surgery, Mr Terry, who is now back at work, said: “I think I have more energy now than I had when I was in my 20s.

“I have made it my life's mission to make people aware of kidney chains.”

Continue reading the main story Checking for a match When an organ becomes available for donation, it is checked to make sure that it is healthy. The blood and tissue type of both donor and recipient are also checked to ensure that they are compatible The better the match, the greater the chance of a successful outcome People from the same ethnic group are more likely to be a close match Those with rare tissue types may only be able to accept an organ from someone of the same ethnic origin

Mr Ruzzamenti told ABC News: “There's some virtue to being kind and helpful to your family and friends but that's easy.

“If the world can be kind and love the stranger and be as kind to them as to their family and friends, world problems would be solved.”

Among the others who took part in the chain were Paulette Behan of West Chicago, and her younger sister, Sunni Stupka of Baldwyn, Mississippi.

Ms Behan needed a kidney transplant, but Ms Stupka's kidney did not match her immune system.

“It broke my heart,” Ms Stupka said. “I felt like a failure, like I had let her down.”

But thanks to the chain, Ms Behan received a kidney from a donor in Pittsburgh who matched her. In return, her sister donated a kidney to a matching patient in California.

Doctors hope that more donations like this record-breaking one can take place.

Dr John Milner, a transplant surgeon at Loyola University Medical Center said: “This is the best way for patients with incompatible donors to be transplanted quickly with the best results.”

Around 400,000 Americans with kidney failure currently undergo daily dialysis, and 4,500 die each year while waiting for a transplant.

The first pooled kidney transplants in the UK took place in 2009.

The transplants involved a donor and recipient couple, who were known to each other but incompatible for transplantation, so were paired with two other donors and recipients in the same situation.

Read the original post:
US record kidney donor chain ends

World's longest kidney transplant chain completed

Wednesday, February 22nd, 2012

ScienceDaily (Feb. 20, 2012) — A Loyola University Medical Center patient has become the final link in the world's longest living-donor kidney transplant chain. The chain involved 30 donors, 30 recipients and 17 hospitals nationwide. Loyola is the only Illinois hospital in the chain.

The final recipient in the chain was Don Terry, 46, of Joliet, Ill., who underwent a kidney transplant at Loyola. His kidney came from a donor in California.

“This kidney chain,” Terry said, “has brought me back to life.”

Living-donor chains have the potential to dramatically reduce transplant waiting times for thousands of patients. Loyola has started 13 kidney transplant chains. That's second only to Cornell, which has started 17 chains, according to the National Kidney Registry, which coordinates kidney chains. In 2011, Loyola started more chains than any other center.

Dr. John Milner, a Loyola transplant surgeon, is a national leader in kidney transplant chains and a member of the Medical Board of the National Kidney Registry. Joe Sinacore, the registry's director of research and education, said Milner is one of the nation's most passionate and effective advocates of kidney chains.

Patients typically must wait as long as 5 to 10 years to receive a kidney from a deceased donor. Having a living donor can eliminate the wait. But in one-third of such cases, a transplant can't be done because the immune systems of the patient and a willing donor don't match.

A kidney chain provides an innovative solution. Each chain begins when a Good Samaritan steps forward to donate a kidney, expecting nothing in return. For example, say the Good Samaritan donates a kidney to a patient we'll call John. John's wife, Mary, would have donated a kidney to her husband, but her kidney doesn't match. So instead of donating to John, Mary “pays it forward” by donating to a second patient, Bill. Bill's sister is willing to donate, but she doesn't match Bill. So she instead gives her kidney to a third patient, who she does match.

The chain can go on indefinitely, moving from hospital to hospital across the country. It stops only when a recipient does not have a friend or family member who can keep the chain going. The previous record for the longest chain, set in 2010 by the National Kidney Registry, was 23 transplants.

The recent record-breaking chain began when a Good Samaritan donated a kidney at Riverside Community Hospital in Riverside, Calif. His kidney was flown cross-country to a recipient at St. Barnabas Medical Center in Livingston, N.J. From there, the chain moved back and forth across the country, stopping at Loyola on the 12th link, and finishing at Loyola on the 30th link.

The last donor in the chain was a 59-year-old California woman. Her kidney was removed at UCLA and flown in the middle of the night to Loyola. Milner and transplant surgeon Amy Lu performed the historic final transplant in the chain.

The chain ended with the Loyola patient, Don Terry, because he did not have an available donor to keep the chain going. His only sibling, a brother, is deceased, and his elderly parents are unable to donate for medical reasons.

The National Kidney Registry ended the chain at Loyola, rather than at another center, because Loyola had started so many previous chains with Good Samaritan donors. This made Loyola eligible based on the registry’s chain-ending policy.

Thirteen chains have started at Loyola. So far, 11 chains have ended at Loyola, benefiting 11 patients who otherwise would have languished on the waiting list. “Loyola has been a beneficiary of its own altruism,” Sinacore said.

Six other Loyola patients have also been involved in transplant chains, bringing the total to 17.

Of the 13 good Samaritans who jump-started kidney transplant chains at Loyola, five are Loyola employees who donated kidneys to strangers. Two other Loyola employees have given kidneys to acquaintances. Collectively, they are known as the Seven Sisters of Loyola. Loyola is believed to be the only organization in the world in which seven employees have donated kidneys to non-relatives.

The National Kidney Registry has coordinated 77 transplant chains that have provided kidneys to 393 patients. That's just a start. Milner said kidney chains have the potential to provide kidneys to as many as 20,000 patients immediately, and 3,000 patients per year thereafter.

“This is the best way for patients with incompatible donors to be transplanted quickly with the best results,” Milner said.

For more information, please call (708) 327-4897 or (800) 424-6120. To speak to a living-donor coordinator at Loyola, call (708) 327-2696.

Paulette's Story: 12th Link in World's Longest Kidney Transplant Chain

Paulette Behan of West Chicago, Ill., and her younger sister, Sunni Stupka of Baldwyn, Miss., are very close.

They text every day and talk at least once a week. So when Sunni learned that Paulette needed a kidney transplant, she was eager to donate one of hers.

But Sunni's kidney didn't match Paulette's immune system. If Sunni donated to Paulette, her kidney would be rejected.

“It broke my heart,” Sunni said. “I felt like a failure, like I had let her down.”

Then the sisters learned about an innovative kidney transplant chain available at Loyola University Medical Center. Transplant surgeon Dr. John Milner explained that Paulette could receive a kidney from a donor in Pittsburgh who matched her. In return, Sunni would promise to donate a kidney to a matching patient in California. Paulette became the 12th link in what would become the world's longest kidney transplant chain.

The kidney from the Pittsburgh donor was flown to Loyola from Allegheny General Hospital in Pittsburgh. Four days after Milner transplanted the kidney into Paulette, Loyola's Chair of Surgery, Dr. Paul Kuo, removed a kidney from Sunni. Sunni's donated kidney then was flown to a waiting patient at Loma Linda University Medical Center.

Don's Story:  Final Link in Record-breaking Kidney Transplant Chain

Don Terry of Joliet, Ill., is the 30th and last recipient in the world's longest kidney-transplant chain.

Terry, 46, has Type 2 diabetes. His kidneys began to fail two years ago, and he went on dialysis in January 2011. He was put on a transplant waiting list and told it could take as long as 5 to 10 years.

Terry has a full-time job with the U.S. Social Security Administration. Being on dialysis, he said, was like having a second, part-time job.

A diabetes patient on dialysis typically does not have a long life expectancy. Terry worried that he might not live to see his 50th birthday. “What bothered me the most was the possibility of leaving family members like my mom and dad by themselves, and having them see their son pass away from an excruciating disease,” he said.

Then Terry read about Loyola University Medical Center's participation in kidney transplant chains, which are designed to eliminate waiting times for kidneys. Terry made an appointment with Dr. John Milner, one of the nation's leading transplant-chain surgeons.

A kidney became available from a donor in California who matched Terry. The surgery was successful, and Terry recently returned to work.

“I think I have more energy now than I had when I was in my 20s,” he said.” I have made it my life's mission to make people aware of kidney chains.”

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by Loyola University Health System, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Continued here:
World's longest kidney transplant chain completed

Panamanian-US Scientific Research Supports Using Fat Stem Cells to Treat Rheumatoid Arthritis

Wednesday, February 22nd, 2012

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients. “Autologous Stromal Vascular Fraction Therapy for Rheumatoid Arthritis: Rationale and Clinical Safety,” which appears in the January publication of the International Archives of Medicine, followed 13 rheumatoid arthritis patients who were treated with their own fat-derived stem cells.

Dallas, TX (PRWEB) February 21, 2012

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients. “Autologous Stromal Vascular Fraction Therapy for Rheumatoid Arthritis: Rationale and Clinical Safety,” which appears in the January publication of the International Archives of Medicine, followed 13 rheumatoid arthritis patients who were treated with their own fat-derived stem cells.

Treating arthritis with fat-derived stem cells has become commonplace in veterinary medicine over the past five years with over 7,000 horses and dogs treated by publication contributor Vet-Stem, a San Diego-based company. The objective of the joint Panamanian-US study was to determine feasibility of translating Vet-Stem's successful animal results into human patients.

Observing no treatment associated adverse reactions after one year, the team concluded that its protocol should be studied further to determine efficacy in the treatment of rheumatoid arthritis. Their publication details the rationale for the use of fat derived stem cells in treatment of autoimmune conditions and is freely available at: http://www.intarchmed.com/content/pdf/1755-7682-5-5.pdf

“Key to advancement of any medical protocol is transparent disclosure of rationale, treatment procedures and outcomes to the research community in a peer-reviewed and IRB-compliant manner,” said Dr. Jorge Paz Rodriguez, Medical Director of the Stem Cell Institute and research team leader. “While we have previously published case studies on the use of fat stem cells in multiple sclerosis patients, and one rheumatoid arthritis patient, this is the first time that comprehensive follow-up has been completed for a larger cohort of patients,” he added.

An important distinction that separates this particular approach from those which are being explored by several international investigators is that the fat stem cells were not grown in a laboratory, affording a substantially higher level of safety and protocol practicality.

“This work signifies Panama's emergence into the burgeoning field of translational medicine,” commented Dr. Ruben Berrocal Timmons, the Panamanian Secretary of Science and publication co-author. “We are proud to have attracted and collaborated with internationally-renowned stem cell clinical researchers such as Dr. Michael Murphy and Dr. Keith March from the Indiana University School of Medicine Center for Vascular Biology and Medicine, Dr. Boris Minev from the University of California, San Diego Moores Cancer Center, Dr. Chien Shing Chen from Loma Linda University Behavioral Medicine Center and Dr. Bob Harman from Vet-Stem. By leveraging their vast, collective clinical experience with Panamanian scientific infrastructure and know-how, we are striving to develop effective, internationally recognized stem cell procedures that will be accepted the world over.”

The treatment procedure involves a mini-liposuction, collection of the fat's cellular component, processing to obtain a population of cells that includes stem cells, freezing the cells in preparation for quality control, and subsequent re-administration of the cells into patients.

The Panamanian-US group has previously shown that there is a specific type of T cell, called the T regulatory cell, associated with fat stem cells, which is capable of suppressing pathological immunity. Their current theory, which is described in detail in the publication: http://www.ncbi.nlm.nih.gov/pubmed/20537320, is that the T regulatory component of the fat is capable of slowing down or suppressing the “autoimmune” reaction, while the stem cell component causes formation of new tissue to replace the damaged joints.

About the Stem Cell Institute

Founded in 2006 on the principles of providing unbiased, scientifically-sound treatment options, the Stem Cell Institute has matured into the world’s leading adult stem cell therapy and research center. In close collaboration with universities and physicians world-wide, the institute’s doctors treat carefully selected patients with spinal cord injury, osteoarthritis, heart disease, multiple sclerosis, rheumatoid arthritis and other autoimmune diseases. Doctors at The Stem Cell Institute have treated over 1000 patients to-date.

For more information on stem cell therapy:

Stem Cell Institute Web Site: http://www.cellmedicine.com

Facebook: http://www.facebook.com/stemcellinstitute

Blogger: http://www.adult-stem-cell-therapy.blogspot.com

Stem Cell Institute

Via Israel & Calle 66

Pacifica Plaza Office #2A

San Francisco, Panama

Republic of Panama

Phone: +1 800 980-STEM (7836) (USA Toll-free) +1 954 636-3390 (from outside USA)

Fax: +1 866 775-3951 (USA Toll-free) +1 775 887-1194 (from outside USA)

###

Jay Lenner
jdlenner@cellmedicine.com
1-800-980-7836
Email Information

Read the original:
Panamanian-US Scientific Research Supports Using Fat Stem Cells to Treat Rheumatoid Arthritis

Turing's tiger stripe theory demonstrated

Wednesday, February 22nd, 2012

ScienceDaily (Feb. 19, 2012) — Researchers from King's College London have provided the first experimental evidence confirming a great British mathematician's theory of how biological patterns such as tiger stripes or leopard spots are formed.

The study, funded by the Medical Research Council and published online in Nature Genetics, not only demonstrates a mechanism which is likely to be widely relevant in vertebrate development, but also provides confidence that chemicals called morphogens, which control these patterns, can be used in regenerative medicine to differentiate stem cells into tissue.

The findings provide evidence to support a theory first suggested in the 1950s by famous code-breaker and mathematician Alan Turing, whose centenary falls this year. He put forward the idea that regular repeating patterns in biological systems are generated by a pair of morphogens that work together as an 'activator' and 'inhibitor'.

To test the theory the researchers studied the development of the regularly spaced ridges found in the roof of the mouth in mice. Carrying out experiments in mouse embryos, the team identified the pair of morphogens working together to influence where each ridge will be formed. These chemicals controlled each other's expression, activating and inhibiting production and therefore controlling the generation of the ridge pattern.

The researchers were able to identify the specific morphogens involved in this process — FGF (Fibroblast Growth Factor) and Shh (Sonic Hedgehog — so-called because laboratory fruit flies lacking the fly version have extra bristles on their bodies). They showed that when these morphogens' activity is increased or decreased, the pattern of the ridges in the mouth palate are affected in ways predicted by Turing's equations. For the first time the actual morphogens involved in this process have been identified and the team were able to see exactly the effects predicted by Turing's 60-year-old speculative theory.

Dr Jeremy Green from the Department of Craniofacial Development at King's Dental Institute said: 'Regularly spaced structures, from vertebrae and hair follicles to the stripes on a tiger or zebrafish, are a fundamental motif in biology. There are several theories about how patterns in nature are formed, but until now there was only circumstantial evidence for Turing's mechanism. Our study provides the first experimental identification of an activator-inhibitor system at work in the generation of stripes — in this case, in the ridges of the mouth palate.

'Although important in feeling and tasting food, ridges in the mouth are not of great medical significance. However, they have proven extremely valuable here in validating an old theory of the activator-inhibitor model first put forward by Alan Turing in the 50s.

'Not only does this show us how patterns such as stripes are formed, but it provides confidence that these morphogens (chemicals) can be used in future regenerative medicine to regenerate structure and pattern when differentiating stem cells into other tissues.

'As this year marks Turing's centenary, it is a fitting tribute to this great mathematician and computer scientist that we should now be able to prove that his theory was right all along!'

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by King's College London.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Andrew D Economou, Atsushi Ohazama, Thantrira Porntaveetus, Paul T Sharpe, Shigeru Kondo, M Albert Basson, Amel Gritli-Linde, Martyn T Cobourne, Jeremy B A Green. Periodic stripe formation by a Turing mechanism operating at growth zones in the mammalian palate. Nature Genetics, 2012; DOI: 10.1038/ng.1090

Note: If no author is given, the source is cited instead.

Disclaimer: Views expressed in this article do not necessarily reflect those of ScienceDaily or its staff.

Read this article:
Turing's tiger stripe theory demonstrated

Arthritis and Lupus Linked To Lower Birth Rates

Wednesday, February 22nd, 2012

Editor's Choice
Academic Journal
Main Category: Lupus
Also Included In: Arthritis / Rheumatology;  Women's Health / Gynecology
Article Date: 21 Feb 2012 – 10:00 PST

email to a friend   printer friendly   opinions  

Current Article Ratings:

Patient / Public:

4.5 (2 votes)

Healthcare Prof:

2 (1 votes)

A multi-center study of a national survey published in Arthritis Care and Research, a journal of the American College of Rheumatology (ACR), has established that over half of women with rheumatoid arthritis (RA) and systematic lupus erythematosus (SLE) have fewer children than desired.

Leading researcher, Kaleb Michaud, Ph.D., assistant professor in the internal medicine department-rheumatology section at the University of Nebraska Medical Center, and his team established that whilst patients' choices are partly responsible for having smaller family sizes, the survey results suggest that higher infertility rates and miscarriages may also affect the number of babies born to those suffering from these chronic conditions.

According to ACR estimates, almost 322,000 U.S. adults suffer from systemic lupus, a disease whereby the body's immune system becomes overactive, attacking healthy cells, tissues, or organs, whilst about 1.3 million adult Americans have RA, a chronic autoimmune disease causing painful joint inflammation. Medical evidence has shown that both RA and SLE are more prevalent in women, and given that the disease often starts to occur during a woman's reproductive years, it can result in problems starting a family.

The study, which was conducted to gain a better insight into reasons of infertility, pregnancy loss and family choice in women with RA and SLE involved surveying 1,017 women registered in the National Data Bank for Rheumatic Diseases, of whom 578 women with RA and 114 with SLE responded.

The researchers categorized the women into three separate groups. Group A consisted of those interested in having children, but who had fewer than planned, Group B consisted of women who wanted children and who had the number of children they planned, and Group C consisted of those who were no longer interested in having children after being diagnosed with RA or SLE.

The results of the study demonstrated that over 60% of participants belonged to Group C, and that 55% of women with RA, and 64% of those with SLE had fewer children than originally planned.

The infertility rate of women with RA in group A was 1.5 times higher, compared with those in group B, however, both groups had similar rates of miscarriage, and even though women with SLE in group A had a comparable number of pregnancies to those in group B, their rate of miscarriage was three times higher. Furthermore, it showed that 42% of women with RA had an overall infertility rate of 42%, and had fewer children than desired.

Women who were diagnosed with RA during their childbearing years had a higher infertility rate, compared with those who were diagnosed after childbearing was complete. There was no substantial increase in fertility in those with SLE, yet women with lupus were observed to have fewer children than desired, which was linked to miscarriage.

Other reasons for fewer pregnancies in women with RA and SLE were reported as the inability to care for their children, adverse effects from medications taken during pregnancy as well as concerns of genetically transmitting the disease to their offspring.

Dr. Michaud said:

“Rheumatoid arthritis and lupus and their treatments can pose major problems for women during pregnancy and can even result in birth defects and spontaneous abortion. We hope this study will bring these reproductive-health concerns to the forefront, especially among women in their childbearing years.”

The researchers indicate that educating patients and raising their awareness of safe medical options during pregnancy, together with effectively controlling these autoimmune diseases will help women to achieve their family planning goals.

Dr. Michaud calls for further studies to investigate the underlying causes of infertility and pregnancy loss in women with RA and SLE.

Written by Petra Rattue
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our lupus section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Petra Rattue. “Arthritis and Lupus Linked To Lower Birth Rates.” Medical News Today. MediLexicon, Intl., 21 Feb. 2012. Web.
22 Feb. 2012. <http://www.medicalnewstoday.com/articles/241958.php>

APA

Please note: If no author information is provided, the source is cited instead.


Rate this article:
(Hover over the stars then click to rate) Patient / Public:
or Health Professional:

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


See the article here:
Arthritis and Lupus Linked To Lower Birth Rates

Progressive Medical Center Atlanta – Atlanta’s Premier Integrative Medicine.mov – Video

Tuesday, February 21st, 2012


15-02-2012 16:32 www.ProgressiveMedicalCenter.com Atlanta Integrative Medicine Progressive Medical Center video on YouTube youtu.be Progressive Medical Center 4646 North Shallowford Rd. Atlanta, Georgia 30338 770-676-6000 Progressive Medical Center is an Integrative Medical Clinic that combines both Conventional and more Natural forms of medicine…THE BEST OF BOTH WORLDS. Intergrative vs. Conventional Medicine: What’s the Difference? Progressive is integrative medicine at its finest. Where conventional (modern) medicine often focuses on treating the symptoms of a disease, Progressive believes that best results are achieved when we get to the root of the problem and then treat the disease accordingly. Conventional Western Medicine is superior in situations that call for trauma intervention, surgery or antibiotic therapy for acute infection, but chronic diseases and conditions are not easily treated by the same system. Alternative and holistic medicine, however, has consistently proven beneficial. For over a decade, Progressive Medical Center has been successfully identifying and treating the core causes of chronic illness and pain. Real Solutions through In-Depth Testing Progressive Medical Center’s comprehensive evaluation methodology enables us to identify the underlying medical conditions that have gone undetected by standard medical testing. Our physicians perform complete physical examinations, all-inclusive diagnostic tests, as well as metabolic, physiological and biochemical

Read this article:
Progressive Medical Center Atlanta – Atlanta’s Premier Integrative Medicine.mov – Video

Summit Veterinary Referral Center Welcomes New Radiology Specialist

Monday, February 20th, 2012

 

 

 

TACOMA, Wash., Feb. 20, 2012 /PRNewswire-iReach/ –  Dr. Macready graduated from the University of California, Davis, College of Veterinary Medicine in 2006.  Upon receiving her Doctorate, she entered a one-year rotating internship in Animal Radiology, Internal Medicine, Surgery, Oncology, Emergency Medicine, Cardiology and Dermatology at Bay Area Veterinary Specialists in San Leandro, CA.  Following the internship, Dr. Macready entered the three-year Radiology Residency program at the University of Tennessee, which she completed in July of 2010.

Dr. Macready is a member of the American College of Veterinary Radiology, and the American Veterinary Medical Association.  She has presented at National and International conferences, and taught CE courses at the University of Tennessee in Small Animal Abdominal Ultrasound and Echocardiogram.  Dr. Macready is the author of numerous peer-reviewed publications and abstracts. 

Summit Veterinary Referral Center is a collective of experienced Emergency/Critical Care, Internal Medicine, Oncology, Neurology, Radiology and Surgery specialists, serving veterinarians and their clients in the Seattle/Tacoma area.  Specialists are available by appointment.  Emergency and critical care services are available 24-hours a day/365 days a year.  For appointments, information and emergency care, telephone (253) 983-1114.

We employ highly skilled and experienced Referral Coordinators, who work one-on-one with a Summit Specialist.  It is their job to ensure that your clients receive individual attention and a thorough explanation of what they can expect from their appointment with the specialist. Referral Coordinators are available Monday – Friday.  Internal Medicine Coordinator – Melissa Schamanski;  Neurology Coordinator – Asya Khesin; Oncology Coordinator – Michelle Thornton; Radiology Coordinator – Darla Renteria; Surgery Coordinator -  Asya Khesin.  

Contact:
Maryle Malloy
Summit Veterinary Referral Center
2505 S 80th St.
Tacoma, WA 98409
(253) 983-1114
maryle@summitvets.com
http://www.summitvets.com

Media Contact: Maryle Malloy Summit Veterinary Referral Center, 2539831114, marylemalloy@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Summit Veterinary Referral Center

Back to top

RELATED LINKS
http://www.summitvets.com

View original post here:
Summit Veterinary Referral Center Welcomes New Radiology Specialist

Kidney transplant chain has links in Chicago

Monday, February 20th, 2012

A history-making kidney transplant chain involving 60 people across the country had two important links in the Chicago area.

The 30 donors and the people they helped didn't know each other and were brought together by a computer match program developed by the National Kidney Registry.

Paulette Behan of West Chicago was number 12 in the chain of recipients. Don Terry of Joliet was number 30, the final link in what is considered the world's longest living-donor kidney transplant chain.

“This kidney chain has brought me back to life,” Terry, 46, said at a news conference at Loyola University Medical Center in Maywood, where he underwent the transplant.

Behan said her sister donated a kidney to a patient in California after Behan received a kidney from someone in Pittsburgh. “She was elated to hear this, that she could help not only me but someone else.”

Dr. John Milner, who performed both surgeries at Loyola, says the operations wouldn’t have been possible without the registry.

“Traditionally  we would have just said, ‘I’m sorry your loved one is going to have to  wait for a kidney transplant,’” Milner said.  “But now through the power of chains at the national level, we can get people transplanted at Loyola as quickly as possible with the best-matched kidneys.”

The chain began with one man in California who just wanted to donate a kidney to someone who needed it.  That was the first piece of the puzzle that linked recipients with living donors across the country.

Terry, who was a diabetes patient on dialysis, said his hopes for a kidney were bleak because waiting for a matching cadaver kidney could have taken years. But a person with his disease typically does not have a long life expectancy.

Terry said he worried that he might not live to see his 50th birthday. “What bothered me the most was the possibility of leaving family members like my mom and dad by themselves, and having them see their son pass away from an excruciating disease,” he said.

Then Terry read about Loyola University Medical Center's participation in kidney transplant chains, which are designed to eliminate waiting times for kidneys. Terry made an appointment with Milner,  one of the nation's leading transplant-chain surgeons.

“I think I have more energy now than I had when I was in my 20s,” Terry said. “I’m hoping that I’m not the last recipient of this chain.”

Behan of West Chicago said her sister from Massachusetts, Sunni Stupka, offered to donate one of her kidneys when she learned Behan needed a transplant.

But Stupka's kidney didn't match Behan's immune system. “It broke my heart,” Stupka said. “I felt like a failure, like I had let her down.”

The sisters said they learned about the kidney transplant chain program at Loyola. Milner told Behan she could receive a kidney from a donor in Pittsburgh who matched her. In return, Stupka would donate a kidney to a matching patient in California.

The kidney from the Pittsburgh donor was flown to Loyola from Allegheny General Hospital in Pittsburgh. Four days after Milner transplanted the kidney into Behan, her sister donated a kidney to a waiting patient at Loma Linda University Medical Center in California.

The National Kidney Registry has coordinated 77 transplant chains that have provided kidneys to 393 patients. Milner said kidney chains have the potential to provide kidneys to as many as 20,000 patients immediately, and 3,000 patients per year thereafter.

“This is the best way for patients with incompatible donors to be transplanted quickly with the best results,” Milner said.

Read more from the original source:
Kidney transplant chain has links in Chicago

Evidence Discovered To Support Turing's Morphogen Theory

Monday, February 20th, 2012

February 20, 2012

A team of UK researchers claims to have put forth the first ever experimental evidence in support of a long-standing theory about how biological patterns such as a leopard’s spots or a tiger’s stripes are formed.

The study was the work of experts from King’s College London, and according to a February 19 press release from the school, “The findings provide evidence to support a theory first suggested in the 1950s by famous code-breaker and mathematician Alan Turing,” who championed the idea that “regular repeating patterns in biological systems are generated by a pair of morphogens that work together as an ‘activator’ and ‘inhibitor’.”

Their work “not only demonstrates a mechanism which is likely to be widely relevant in vertebrate development, but also provides confidence that chemicals called morphogens, which control these patterns, can be used in regenerative medicine to differentiate stem cells into tissue,” the college added.

In order to test their theory, the King’s College London researchers analyzed the development of regularly-spaced ridges that can be found in the mouths of mice.

By conducting experiments using embryos of the rodents, they were able to discover the pair of morphogens that work together to help determine where each of the ridges will be formed. Each chemical influenced the other, the university said, alternately activating or inhibiting production in order to control the creation of the ridge pattern on the roof of a mouse’s mouth.

The morphogens involved in the process were identified by the scientists as Fibroblast Growth Factor (FGF) and Sonic Hedgehog (Shh), and by studying them, they learned that when each chemical’s activity is increased or decreased, it affected the pattern of the ridges in the mouth in the same way that Turing’s equations had predicted they would.

“For the first time the actual morphogens involved in this process have been identified and the team were able to see exactly the effects predicted by Turing’s 60-year-old speculative theory,” the college press release stated.

“Regularly spaced structures, from vertebrae and hair follicles to the stripes on a tiger or zebrafish, are a fundamental motif in biology. There are several theories about how patterns in nature are formed, but until now there was only circumstantial evidence for Turing’s mechanism. Our study provides the first experimental identification of an activator-inhibitor system at work in the generation of stripes – in this case, in the ridges of the mouth palate,” Dr. Jeremy Green from the Department of Craniofacial Development at King’s Dental Institute added in a statement.

While Green admitted that the discovery was “not of great medical significance,” he said that they are “extremely valuable” in validating Turing’s theories from the 1950s. He also says that their discovery has made them confident that these morphogen chemicals could be used in the future to create regenerative medicine to heal or recreate structures and/or patterns when turning stem cells into other types of tissues.

The research was funded by the Medical Research Council and is published online in the journal Nature Genetics.

Turing, who was born on June 23, 1912 and would have turned 100 this year, has been referred to by some as the father of computer science and artificial intelligence. During World War II, he served as a member of the Government Code and Cypher School (GCCS) at Bletchley Park in the field of naval cryptanalysis.

Turing later went on to join the National Physical Laboratory, where he created one of the very first stored-program computer designs, in 1948 he assisted in the development of computers at Manchester University. His paper “The Chemical Basis of Morphogenesis,” in which he first put forth his theory of pattern formation, was published by Philosophical Transactions of the Royal Society of London in August 1952.

On the Net:

Source: RedOrbit Staff & Wire Reports

Visit link:
Evidence Discovered To Support Turing's Morphogen Theory

Judi Dench fighting blindness

Monday, February 20th, 2012

20 Feb – Veteran actress Judi Dench recently revealed that of late, she had been battling with macular degeneration that could cause her to go blind, according to Access Hollywood.

Best known for her role as M in the Bond franchise, Dench said that her eyesight was getting worse due to her medical condition and at this point of time, she could not even read her movie scripts.

The Academy Award-winner needed assistance from her family members to memorize her lines.

“It's usually my daughter or my agent or a friend and actually I like that, because I just sit there and imagine the story in my mind,” explained the 78-year-old actress.

She added, “The most distressing thing is in a restaurant in the evening, because I can't see the person I'm having dinner with.”

Dench is currently working on the latest Bond movie, “Skyfall”, in London and said that despite her condition, she would not retire from acting.

“As long as there is a possibility of working I'm not going to retire because if I retire nothing will work any more and it's hard enough as it is.”

Since the beginning of her illustrious career in 1957, Dench had been producing great performances in both theatre and cinema. She won the Academy Award for her supporting role in “Shakespeare in Love”, two Golden Globes, ten BAFTA awards and two Screen Actors Guild Awards.

Here is the original post:
Judi Dench fighting blindness

Symposium discusses links between genetic, epigenetic and environmental influences on autism

Monday, February 20th, 2012

Two UC Davis MIND Institute researchers will lead a symposium on relationships between genetic, epigenetic and environmental influences on the development of autism in children during the American Association for the Advancement of Science (AAAS) Annual Meeting, Feb. 16 -18 in Vancouver, Canada.

The symposium, “Autism: Genetic, Epigenetic and Environmental Factors Influencing Neural Networks,” will be held Feb. 18. The researchers, both affiliated with the UC Davis MIND Institute, are Isaac Pessah, director of the UC Davis Children's Center for Environmental Health and Disease Prevention and a professor in the UC Davis School of Veterinary Medicine, and Janine LaSalle, professor in the Department of Medical Microbiology and Immunology and in the Rowe Program in Human Genetics.

A news briefing on the symposium will be held at 9 a.m. on Feb. 19 in Room 221 on the second Level of the Vancouver Convention Center.

Autism is a heterogeneous set of developmental disorders with complex etiologies. The goal of the symposium is to present a multidisciplinary perspective on how genetic, epigenetic and environmental factors can interact to promote autism risk. Other presenters will include symposium co-organizer Cindy Lawler of the National Institute of Environmental Health Sciences, Scott Selleck of Pennsylvania State University and Pat Leavitt of the University of Southern California.

Read more:
Symposium discusses links between genetic, epigenetic and environmental influences on autism

Scientists prove Turing's tiger stripe theory

Sunday, February 19th, 2012

Public release date: 19-Feb-2012
[ | E-mail | Share ]

Contact: Katherine Barnes
katherine.barnes@kcl.ac.uk
44-020-784-83076
King's College London

Researchers from King's College London have provided the first experimental evidence confirming a great British mathematician's theory of how biological patterns such as tiger stripes or leopard spots are formed.

The study, funded by the Medical Research Council and to be published online in Nature Genetics, not only demonstrates a mechanism which is likely to be widely relevant in vertebrate development, but also provides confidence that chemicals called morphogens, which control these patterns, can be used in regenerative medicine to differentiate stem cells into tissue.

The findings provide evidence to support a theory first suggested in the 1950s by famous code-breaker and mathematician Alan Turing, whose centenary falls this year. He put forward the idea that regular repeating patterns in biological systems are generated by a pair of morphogens that work together as an 'activator' and 'inhibitor'.

To test the theory the researchers studied the development of the regularly spaced ridges found in the roof of the mouth in mice. Carrying out experiments in mouse embryos, the team identified the pair of morphogens working together to influence where each ridge will be formed. These chemicals controlled each other's expression, activating and inhibiting production and therefore controlling the generation of the ridge pattern.

The researchers were able to identify the specific morphogens involved in this process ? FGF (Fibroblast Growth Factor) and Shh (Sonic Hedgehog ? so-called because laboratory fruit flies lacking the fly version have extra bristles on their bodies). They showed that when these morphogens' activity is increased or decreased, the pattern of the ridges in the mouth palate are affected in ways predicted by Turing's equations. For the first time the actual morphogens involved in this process have been identified and the team were able to see exactly the effects predicted by Turing's 60-year-old speculative theory.

Dr Jeremy Green from the Department of Craniofacial Development at King's Dental Institute said: 'Regularly spaced structures, from vertebrae and hair follicles to the stripes on a tiger or zebrafish, are a fundamental motif in biology. There are several theories about how patterns in nature are formed, but until now there was only circumstantial evidence for Turing's mechanism. Our study provides the first experimental identification of an activator-inhibitor system at work in the generation of stripes ? in this case, in the ridges of the mouth palate.

'Although important in feeling and tasting food, ridges in the mouth are not of great medical significance. However, they have proven extremely valuable here in validating an old theory of the activator-inhibitor model first put forward by Alan Turing in the 50s.

'Not only does this show us how patterns such as stripes are formed, but it provides confidence that these morphogens (chemicals) can be used in future regenerative medicine to regenerate structure and pattern when differentiating stem cells into other tissues.

'As this year marks Turing's centenary, it is a fitting tribute to this great mathematician and computer scientist that we should now be able to prove that his theory was right all along!'

###

CONTACT
Katherine Barnes
International Press Officer
King's College London
Tel: 44-207-848-3076
Email: katherine.barnes@kcl.ac.uk

NOTES TO EDITORS

Copies of the paper available on request ? please contact press@nature.com

About King's College London (www.kcl.ac.uk)

King's College London is one of the top 30 universities in the world (2011/12 QS World University Rankings), and the fourth oldest in England. A research-led university based in the heart of London, King's has nearly 23,500 students (of whom more than 9,000 are graduate students) from nearly 140 countries, and some 6,000 employees. King's is in the second phase of a ?1 billion redevelopment programme which is transforming its estate.

King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly ?450 million.

King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar. It is the largest centre for the education of healthcare professionals in Europe; no university has more Medical Research Council Centres.

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit: http://www.kingshealthpartners.org.

The College is in the midst of a five-year, ?500 million fundraising campaign ? World questions|King's answers ? created to address some of the most pressing challenges facing humanity as quickly as feasible. The campaign's three priority areas are neuroscience and mental health, leadership and society, and cancer. More information about the campaign is available at http://www.kcl.ac.uk/kingsanswers.

About Medical Research Council (http://www.mrc.ac.uk)

For almost 100 years the Medical Research Council has improved the health of people in the UK and around the world by supporting the highest quality science. The MRC invests in world-class scientists. It has produced 29 Nobel Prize winners and sustains a flourishing environment for internationally recognised research. The MRC focuses on making an impact and provides the financial muscle and scientific expertise behind medical breakthroughs, including one of the first antibiotics penicillin, the structure of DNA and the lethal link between smoking and cancer. Today MRC funded scientists tackle research into the major health challenges of the 21st century.


[ | E-mail | Share ]

 

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read more:
Scientists prove Turing's tiger stripe theory

Dijaya boss in healthcare venture

Sunday, February 19th, 2012

TAN Sri Danny Tan Chee Sing, who controls Dijaya Group, has ventured into the healthcare business, following in the footsteps of elder brother Tan Sri Vincent Tan Chee Yioun.

The younger Tan is partnering several doctors to operate the Beverly Wilshire Medical Centre Sdn Bhd, to capture a piece of the booming aesthetic industry here.

“Beverly Wilshire is a boutique medical centre specialising in aesthetics, plastic, stem cell therapy and health screening,” its executive director Dr Liow Tiong Sin told Business Times in a recent interview.

This 13-bed hospital also has a dental unit, operated by Beverly Wilshire Dental Specialist Centre Sdn Bhd, which has Tan as a common shareholder.

In total, the facility will have six medical doctors – including two surgeons, four physicians and five dental surgeons.

“This is a centre that provides total transformation for the patient. We provide a high standard of service, individual service that ensures patients don't feel like hospital patients but rather a place for healing and rejuvenation,” Dr Liow, who is also the aesthetic physician, said.

It is also a one-stop centre for transformation and healthy aging, providing both external and internal treatment.

All its equipment are FDA approved. Its machines include Fraxel for scar, pigment and skin rejuvenation and Thermage CPT, which is used to firm skin, improve cellulite, body tightening and sculpting.

How is this centre different from other beauty centres and medical centres providing similar services?

“Others may not be focused and built to specialise on aesthetics. We trust we are the only one-stop place which offers treatment from plastic (surgery) to anti-aging, to stem cell to dental,” he said.

Beverly Wilshire uses human stem cells as it is the most bio-compatible. At the same time, stem cells can also be harvested in the purest form from a person's fat cell for an autologous transplant.

Stem cell therapy is used to regenerate the muscle and vessels in the heart and in the brain to regenerate the nerves and improve blood supply.

While most hospitals in Malaysia would typically take about 10 years to see return on investments (ROI), Beverly Wilshire expects to see ROI in less than half that time or less. Its expected investment cost is some RM20 million.

“This is a boutique type centre. ROI could take three to five years,” he said.

Beverly Wilshire, started as a privately held Dijaya Medical Centre but decided to change its name as the name Dijaya is closely linked to property.

Since it is a beauty and aesthetics centre, it searched for names and settled with Beverly Wilshire as it was a luxury hotel in Beverly Hills in the US.

“So we thought we will create the Hollywood theme and provide the best,” Dr Liow said.

This 13-bed hospital is located at Plaza Dijaya in Jalan Tun Razak, Kuala Lumpur. It will be launched soon.

It will target both locals and foreigners. For some foreign patients, the treatment will be a fraction of the cost compared to the same treatment in their country.

Continued here:
Dijaya boss in healthcare venture

Synthetic protein amplifies genes needed for stem cells

Saturday, February 18th, 2012

ScienceDaily (Feb. 16, 2012) — Scientists have found a way to generate and maintain stem cells much more efficiently by amplifying the effect of an essential protein.

Researchers from Denmark, Scotland and the USA have created synthetic versions of a protein, which manipulates adult cells — such as skin cells — so that they can subsequently revert to an earlier, embryonic like state. These reverted cells have the potential to become any cell in the body.

As well as reverting adult cells to this state — known as induced pluripotent stem cells , the protein also plays a key role in maintaining embryonic stem cells in a pure form. If the protein — Oct4 — is not present, the embryonic stem cells will start to differentiate into specific cells.

In order to reprogamme adult cells to have stem cell properties viruses need to be added to cell cultures to trigger production of significant quantities of Oct4.

Oct4 plays a powerful role in regulating stem cell genes. However, while large quantities of Oct4 are needed too much of it can ruin the properties of stem cells.

Scientists, whose work is published in the journal Cell Reports, were able to overcome this by producing a synthetic version of Oct4 that amplified the effect of the protein in its natural form.

The synthetic version of Oct4 was much more efficient in turning on genes that instruct cells on how to be stem cells and, as a result, the cells did not need as much Oct4 for either reprogramming or to remain as stem cells — thereby eliminating problems caused by too much Oct4.

In fact, the synthetic Oct4 could support stem cells under conditions that they do not normally grow. These findings could also help scientists find new ways generate stem cells in the laboratory.

The study showed that Oct4 was mainly responsible for turning on genes that instruct cells on how to become stem cells, rather than turning off genes that encourage the cells to differentiate.

“Our discovery is an important step towards generating and maintaining stem cells much more effectively,” says Professor Joshua Brickman, affiliated with both The Danish Stem Cell Center (DanStem), University of Copenhagen and Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh.

“Embryonic stem cells are characterized, among other things, by their ability to perpetuate themselves indefinitely and differentiate into all the cell types in the body — a trait called pluripotency. But to be able to use them medically, we need to be able to maintain them in a pure state, until they're needed. When we want to turn a stem cell into a specific cell, such as insulin producing beta cell, or a nerve cell in the brain, we'd like this process to occur accurately and efficiently. This will not be possible if we don't understand how to maintain stem cells as stem cells. As well as maintaining embryonic stem cells in their pure state more effectively, the artificially created Oct4 was also more effective at reprogramming adult cells into so-called induced Pluripotent Stem cells, which have many of the same traits and characteristics as embryonic stem cells but can derived from the patients to both help study degenerative disease and eventually treat them.”

Oct4 is a so-called transcription factor — a protein that binds to specific DNA sequences, thereby controlling the flow (or transcription) of genetic information from DNA to mRNA. The synthetic version of Oct4 was created by using recombinant DNA technology whereby a gene was modified to produce new and more active protein. The modified gene was either introduced into stem cells or used to reprogram adult skin cells.

If scientists can exploit this programming of stem cell programs, it will improve the ability to generate stem cells directly from a patient. These cells could in turn potentially be used for individualised studies and for developing individualized therapies for degenerative diseases such as type 1 diabetes and neuro-degenerative diseases.

The study involved mouse embryonic stem cells, early embryonic progenitors cells in frogs as well as iPS cells from both mouse and human sources. The research was supported by grants from the Novo Nordisk Foundation (DK), the Medical Reseach Council and the Biotechnology and Biological Sciences Research Council (MRC and BBSRC, UK).

Recommend this story on Facebook, Twitter,
and Google +1:

Other bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of Edinburgh.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Fella Hammachi, Gillian M. Morrison, Alexei A. Sharov, Alessandra Livigni, Santosh Narayan, Eirini P. Papapetrou, James O'Malley, Keisuke Kaji, Minoru S.H. Ko, Mark Ptashne, Joshua M. Brickman. Transcriptional Activation by Oct4 Is Sufficient for the Maintenance and Induction of Pluripotency. Cell Reports, 2012; DOI: 10.1016/j.celrep.2011.12.002

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Read more:
Synthetic protein amplifies genes needed for stem cells

Countries With The Highest Healthcare Spending

Saturday, February 18th, 2012

According to the Economist magazine, by a fairly wide margin, the United States is the biggest spender on healthcare in the world. This is both in terms of the percentage of healthcare spending of total gross domestic product (GDP), as well as per capita, or per person. Looking at GDP, healthcare accounts for 16% of the total pie. And in terms of per capita spending, the U.S. again leads at just over $7,500 per individual.

Big Spenders
Returning to GDP, the next biggest spenders are in Europe. Both France and Belgium spend around 11% of GDP on healthcare expenditures. This is followed by Switzerland, Canada, Germany and Austria at somewhere between 10 and 11%. The vast majority of other developed countries are in the high single digits, and the average of this group is 10.1%. Laggards, which are a good thing when it comes to total spending, include the U.K., Spain and Japan, all of which are around 7%.

In terms of growth, back in 2000 the average was 9%, meaning that healthcare spending across the globe continues to outpace overall economic growth. Again, the U.S. has experienced among the highest healthcare inflation. Back in 2000, it spent 13.4% of GDP on healthcare spending, which again was the highest in the world. However, other countries with aging populations, including Japan and Italy, have also seen above-average rises in spending.

Trends
The growth trend in health care spending doesn't look to be slowing down. In the U.S., a recent study by the Congressional Budget Office estimated that spending could double in the next decade. By 2022, it expects the U.S. to spend $1.8 trillion on healthcare. Roughly half of this will go to spending on the elderly while another significant percentage is projected to help lower income individuals pay for insurance, which is part of latest round of health care regulations.

Looking at the nearer-term growth trends, the U.S. is surprisingly a laggard. Returning to same Economist data, in 2012 the total U.S. and North American healthcare spending will rise a more modest 4.7%. Asia is expected to lead the way with a growth of 11.7% and will be followed closely by Eastern Europe and Russia at 11.6%. The Middle East and Africa will grow by 10.7% and Latin America a more modest 8.3%. Western Europe will actually see a 1.6% decline in spending, due in good part to sovereign debt issues that are slowing economic growth.

Challenges
Digging a bit deeper, spending on the elderly is rising across the world as the population ages. Obesity challenges, especially in the U.S. are accounting for a rising proportion of total healthcare spending. Smoking-related illnesses, including lung cancer and heart disease, are significant but no longer increasing rapidly as anti-smoking campaigns, especially in developed countries such as the U.S., lower the overall number of smokers.

Focusing on preventative medicine, such as increasing health and overall well-being activities, could save trillions in healthcare spending across the globe. One study in the U.S. estimated that better control of hypertension in the elderly or diabetes and heart disease care for the overweight and obese could end up saving hundreds of billions going forward.

Another interesting question is why the excessive spending in the U.S. doesn't lead to world-leading healthcare statistics. The U.S. is the world's leading healthcare spender, but is actually towards the bottom of the list in terms of average life expectancy. Japan leads the way, with an average life expectancy of more than 81 years, to provide one of the best values given its low healthcare spending as a percentage of GDP. The U.S. is right next to Cuba at right around 77 years, with only a few countries at the bottom closer to 76 years of age.

The Bottom Line
A key takeaway, especially by looking at the high spending in the U.S., is that the most spending does not mean the best healthcare. Improved efficiencies are key to improving the cost/benefit tradeoff when it comes to healthcare spending. A McKinsey article from 2010 looked at an initiative in Ireland to reform its healthcare industry, and found that improving efficiency can have the most beneficial impact. It found that coordinating efforts among different providers for the same patient can reduce spending. It also modernized many hospitals and switched some services to larger hospitals with better economies of scale.

In the U.S., a primary criticism is that doctors and other medical professionals are incentivized to increase the number of procedures and tests because more activity means more revenue. A shift to preventative medicine and a focus on quality of care could help reduce spending growth and also make the system more efficient.

More From Investopedia

Go here to see the original:
Countries With The Highest Healthcare Spending

Synthetic Oct4 protein more effective at turning genes into pluripotent stem cells

Friday, February 17th, 2012

Scientists have found a way to generate and maintain stem cells much more efficiently by amplifying the effect of an essential protein.

Researchers from Denmark, Scotland and the USA have created synthetic versions of a protein, which manipulates adult cells – such as skin cells – so that they can subsequently revert to an earlier, embryonic like state. These reverted cells have the potential to become any cell in the body.

As well as reverting adult cells to this state – known as induced pluripotent stem cells , the protein also plays a key role in maintaining embryonic stem cells in a pure form. If the protein – Oct4 – is not present, the embryonic stem cells will start to differentiate into specific cells.

In order to reprogamme adult cells to have stem cell properties viruses need to be added to cell cultures to trigger production of significant quantities of Oct4.

Oct4 plays a powerful role in regulating stem cell genes. However, while large quantities of Oct4 are needed too much of it can ruin the properties of stem cells.

Scientists, whose work is published in the journal Cell Reports, were able to overcome this by producing a synthetic version of Oct4 that amplified the effect of the protein in its natural form.

The synthetic version of Oct4 was much more efficient in turning on genes that instruct cells on how to be stem cells and, as a result, the cells did not need as much Oct4 for either reprogramming or to remain as stem cells – thereby eliminating problems caused by too much Oct4.

In fact, the synthetic Oct4 could support stem cells under conditions that they do not normally grow. These findings could also help scientists find new ways generate stem cells in the laboratory.

The study showed that Oct4 was mainly responsible for turning on genes that instruct cells on how to become stem cells, rather than turning off genes that encourage the cells to differentiate.

“Our discovery is an important step towards generating and maintaining stem cells much more effectively,” says Professor Joshua Brickman, affiliated with both The Danish Stem Cell Center (DanStem), University of Copenhagen and Medical Research Council Centre for Regenerative Medicine at the University of Edinburgh.

Read the rest here:
Synthetic Oct4 protein more effective at turning genes into pluripotent stem cells





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research